Co-Expression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist Improves Human Islet Survival and Function
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have previously shown the improvement in islet function and vascularization following ex vivo transfection for human vascular endothelial growth factor (hVEGF) gene expression. In this study, we tested the hypothesis that co-expression of two genes, which target different challenges faced by islets post-transplantation, supplement each other to improve the survival and function of islets. We determined whether there is an additive effect of hVEGF and human interleukin-1 receptor antagonist (hIL-1Ra) gene expression in human islets.
Materials and Methods
Human islets were co-infected with adenoviral vectors encoding hVEGF and hIL-1Ra. Islets were then incubated with a cocktail of inflammatory cytokines (IL-1β+TNFα+IFNγ), and islet viability and function were determined. In vivo function was evaluated by transplanting islets under the kidney capsules of streptozotocin-induced non-obese diabetic severe combined immunodeficient (NOD-SCID) mice.
Infection of human islets with Adv-hVEGF and/or Adv-hIL-1Ra inhibited expression of inducible nitric oxide synthase (iNOS), decreased the production of nitric oxide (NO), and prevented the loss of in vitro glucose-stimulated insulin response and viability. Moreover, co-expression of hVEGF and hIL-1Ra reduced the blood glucose level of mice, and increased the level of blood insulin and c-peptide upon glucose challenge.
Our results indicated that co-expression of genes that target different insults to transplanted islets can improve the outcome of islet transplantation better than either gene alone.
- A. M. Shapiro, J. R. Lakey, E. A. Ryan, G. S. Korbutt, E. Toth, G. L. Warnock, N. M. Kneteman, and R. V. Rajotte. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343:230–238 (2000). CrossRef
- D. Pipeleers, B. Keymeulen, L. Chatenoud, C. Hendrieckx, Z. Ling, C. Mathieu, B. Roep, and D. Ysebaert. A view on beta cell transplantation in diabetes. Ann. N. Y. Acad. Sci. 958:69–76 (2002). CrossRef
- T. Berneyand and C. Ricordi. Islet cell transplantation: the future? Langenbecks Arch. Surg. 385:373–378 (2000). CrossRef
- P. B. Caroll. Anatomy and Physiology of Islets of Langerhans. In C. Ricordi (ed.), Pancreatic Islet Cell Transplantation: 1892–1992 One Century of Transplantation for Diabetes, Landes Bioscience, Georgetown, Texas, 1990, pp. 7–25.
- A. S. Narang, K. Cheng, J. Henry, C. Zhang, O. Sabek, D. Fraga, M. Kotb, A. O. Gaber, and R. I. Mahato. Vascular endothelial growth factor gene delivery for revascularization in transplanted human islets. Pharm. Res. 21:15–25 (2004). CrossRef
- R. I. Mahato, J. Henry, A. S. Narang, O. Sabek, D. Fraga, M. Kotb, and A. O. Gaber. Cationic lipid and polymer-based gene delivery to human pancreatic islets. Molec. Ther. 7:89–100 (2003). CrossRef
- K. Cheng, D. Fraga, C. Zhang, M. Kotb, A. O. Gaber, R. V. Guntaka, and R. I. Mahato. Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. Gene Ther. 11:1105–1116 (2004). CrossRef
- A. S. Narang, L. Thoma, D. D. Miller, and R. I. Mahato. Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug. Chem. 16:156–168 (2005). CrossRef
- N. Zhang, A. Richter, J. Suriawinata, S. Harbaran, J. Altomonte, L. Cong, H. Zhang, K. Song, M. Meseck, J. Bromberg, and H. Dong. Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 53:963–970 (2004). CrossRef
- P. Vajkoczy, A. M. Olofsson, H. A. Lehr, R. Leiderer, F. Hammersen, K. E. Arfors, and M. D. Menger. Histogenesis and ultrastructure of pancreatic islet graft microvasculature. Evidence for graft revascularization by endothelial cells of host origin. Am. J. Pathol. 146:1397–1405 (1995).
- V. Hadjivassiliou, M. H. Green, R. F. James, S. M. Swift, H. A. Clayton, and I. C. Green. Insulin secretion, DNA damage, and apoptosis in human and rat islets of Langerhans following exposure to nitric oxide, peroxynitrite, and cytokines. Nitric Oxide 2:429–441 (1998). CrossRef
- T. Dobson, D. Fraga, C. Saba, M. Bryer-Ash, A. O. Gaber, and I. C. Gerling. Human pancreatic islets transfected to produce an inhibitor of TNF are protected against destruction by human leukocytes. Cell Transplant 9:857–865 (2000).
- J. O. Sandberg, D. L. Eizirik, S. Sandler, D. E. Tracey, and A. Andersson. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 42:1845–1851 (1993). CrossRef
- C. Gysemans, K. Stoffels, A. Giulietti, L. Overbergh, M. Waer, M. Lannoo, U. Feige, and C. Mathieu. Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents. Diabetologia 46:1115–1123 (2003). CrossRef
- N. Giannoukakis, W. A. Rudert, S. C. Ghivizzani, A. Gambotto, C. Ricordi, M. Trucco, and P. D. Robbins. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 48:1730–1736 (1999). CrossRef
- J. A. Corbett, M. A. Sweetland, J. L. Wang, J. R. Lancaster, Jr., and M. L. McDaniel. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc. Natl. Acad. Sci. USA 90:1731–1735 (1993). CrossRef
- M. Arnush, M. R. Heitmeier, A. L. Scarim, M. H. Marino, P. T. Manning, and J. A. Corbett. IL-1 produced and released endogenously within human islets inhibits beta cell function. J. Clin. Invest. 102:516–526 (1998). CrossRef
- D. L. Eizirik, S. Sandler, N. Welsh, M. Cetkovic-Cvrlje, A. Nieman, D. A. Geller, D. G. Pipeleers, K. Bendtzen, and C. Hellerstrom. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J. Clin. Invest. 93:1968–1974 (1994). CrossRef
- A. O. Gaber, D. W. Fraga, C. S. Callicutt, I. C. Gerling, O. M. Sabek, and M. Y. Kotb. Improved in vivo pancreatic islet function after prolonged in vitro islet culture. Transplantation 72:1730–1736 (2001). CrossRef
- S. Rodriguez-Muleroand and E. Montanya. Selection of a suitable internal control gene for expression studies in pancreatic islet grafts. Transplantation 80:650–652 (2005). CrossRef
- S. Bertera, A. M. Alexander, M. L. Crawford, G. Papworth, S. C. Watkins, P. D. Robbins, and M. Trucco. Gene combination transfer to block autoimmune damage in transplanted islets of Langerhans. Exp. Diabesity Res. 5:201–210 (2004). CrossRef
- T. B. Mysore, T. A. Shinkel, J. Collins, E. J. Salvaris, N. Fisicaro, L. J. Murray-Segal, L. E. Johnson, D. A. Lepore, S. N. Walters, R. Stokes, A. P. Chandra, P. J. O'Connell, A. J. d'Apice, and P. J. Cowan. Overexpression of glutathione peroxidase with two isoforms of superoxide dismutase protects mouse islets from oxidative injury and improves islet graft function. Diabetes 54:2109–2116 (2005). CrossRef
- V. V. Tran, G. Chen, C. B. Newgard, and H. E. Hohmeier. Discrete and complementary mechanisms of protection of beta-cells against cytokine-induced and oxidative damage achieved by bcl-2 overexpression and a cytokine selection strategy. Diabetes 52:1423–1432 (2003). CrossRef
- M. S. Baker, X. Chen, A. Rotramel, J. Nelson, and D. B. Kaufman. Proinflammatory cytokines induce NF-kappaB-dependent/NO-independent chemokine gene expression in MIN6 beta cells. J. Surg. Res. 110:295–303 (2003). CrossRef
- F. T. Thomas, A. Hutchings, J. Contreras, J. Wu, X. L. Jiang, D. Eckhoff, and J. M. Thomas. Islet transplantation in the twenty-first century. Immunol. Res. 26:289–296 (2002). CrossRef
- R. I. Mahato, K. Cheng, and R. V. Guntaka. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Exp. Opin. Drug Del. 2:1–26 (2005). CrossRef
- M. J. Kim, G. R. Ryu, J. H. Kang, S. S. Sim, S. Min do, D. J. Rhie, S. H. Yoon, S. J. Hahn, I. K. Jeong, K. J. Hong, M. S. Kim, and Y. H. Jo. Inhibitory effects of epicatechin on interleukin-1beta-induced inducible nitric oxide synthase expression in RINm5F cells and rat pancreatic islets by down-regulation of NF-kappaB activation. Biochem. Pharmacol. 68:1775–1785 (2004). CrossRef
- S. Abdelli, J. Ansite, R. Roduit, T. Borsello, I. Matsumoto, T. Sawada, N. Allaman-Pillet, H. Henry, J. S. Beckmann, B. J. Hering, and C. Bonny. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes 53:2815–2823 (2004). CrossRef
- D. Liu, D. Pavlovic, M. C. Chen, M. Flodstrom, S. Sandler, and D. L. Eizirik. Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS−/−). Diabetes 49:1116–1122 (2000). CrossRef
- P. Ylipaasto, K. Klingel, A. M. Lindberg, T. Otonkoski, R. Kandolf, T. Hovi, and M. Roivainen. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia 47:225–239 (2004). CrossRef
- C. A. Delaney, D. Pavlovic, A. Hoorens, D. G. Pipeleers, and D. L. Eizirik. Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology 138:2610–2614 (1997). CrossRef
- Co-Expression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist Improves Human Islet Survival and Function
Volume 23, Issue 9 , pp 1970-1982
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- gene therapy
- interleukin-1 receptor antagonist
- vascular endothelial growth factor
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmaceutical Sciences, University of Tennesee Health Science Center, 26 S Dunlap St., Feurt Bldg RM 413, Memphis, Tennessee, 38163, USA
- 2. Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, 38163, USA